✦ LIBER ✦

Clinical relevance of PET scan in stage III & IV melanoma patients

✍ Scribed by Stas, M.; Stroobants, S.; Dupont, P.; Gysen, M.; Van Hoe, L.; Mulier, S.; Garmyn, M.; De Wever, I.

Book ID: 122549881
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 155 KB
Volume: 35
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(99)81920-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Positron emission tomography scanning in

Positron emission tomography scanning in malignant melanoma : Clinical utility in patients with Stage III disease

✍ Douglas S. Tyler; Mark Onaitis; Aftab Kherani; Ankie Hata; Evelyn Nicholson; Mar 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 281 KB 👁 2 views

VEGF-SPECT with 111In-bevacizumab in sta

VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients

✍ Wouter B. Nagengast; Marjolijn N. Lub-de Hooge; Esther M.E. van Straten; Schelto 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 701 KB

Clinical Value of Radiographic Staging i

Clinical Value of Radiographic Staging in Patients Diagnosed With AJCC Stage III Melanoma

✍ Prakash K. Pandalai; Francisco J. Dominguez; James Michaelson; Kenneth K. Tanabe 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 193 KB

The cost of unresectable stage III or st

The cost of unresectable stage III or stage IV melanoma in Italy

✍ Michele Maio, Paolo Ascierto… 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 589 KB

Skin biopsies in DC vaccines for stage I

Skin biopsies in DC vaccines for stage III–IV melanoma patients: Role of neutrophils?

✍ M. Laporte; M. Trakatelli; P. Vereecken; D. Blocklet; M. Lespagnard; M. Petein; 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 337 KB

Detection of mutated BRAFV600E variant i

Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patients

✍ Maria Daniotti; Viviana Vallacchi; Licia Rivoltini; Roberto Patuzzo; Mario Santi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 187 KB

## Abstract BRAFV600E is the most represented somatic point mutation in cutaneous melanoma, thus providing a unique molecular marker for this disease. The development of efficient methods for its detection in free circulating DNA of patients may lead to the improvement of diagnostic and prognostic